Maldonado Jonathan, Drevik Johnathan A, Walcott Quinnlyn, Adams Jacob, Knowles Taylor, Holzbeierlein Helen, Letner George, Holzbeierlein Jeffrey M, Wulff-Burchfield Elizabeth, Lee Eugene K
Department of Urology, School of Medicine, The University of Kansas, Kansas City, Kansas 66045, United States of America.
Department of Internal Medicine, School of Medicine, The University of Kansas, Kansas City, Kansas 66045, United States of America.
Bladder (San Franc). 2025 May 29;12(3):e21200044. doi: 10.14440/bladder.2025.0008. eCollection 2025.
Bladder cancer, specifically urothelial carcinoma (UC), poses a significant health concern in the United States and is significantly influenced by tobacco use. Despite its prevalence, routine UC screening is not recommended due to diagnostic limitations and uncertain benefits in long-term survival.
This study examined the effectiveness of urine dipstick screening for UC in subjects already at elevated risk for UC due to substantial smoking histories, who were undergoing low-dose computed tomography (LDCT) for lung cancer screening.
A prospective study was conducted at a single academic center to screen patients undergoing annual LDCT for lung cancer screening for UC. Urine dipstick tests were performed on patients without a history of gross hematuria or previously diagnosed as having UC. Statistical analyses were used to evaluate the relationship between smoking history, urinalysis results, and the prevalence of urological malignancies.
We enrolled 201 patients with a mean age of 64.4 years and a balanced gender distribution. Urine dipstick tests detected red blood cells (RBCs) in 15% of patients, with 2.1% showing microhematuria on formal urinalysis (>2 RBC/high power field). Nine (4.5%) participants were advised to undergo comprehensive hematuria evaluations. In addition, four (2%) participants had a history or were newly diagnosed with urological malignancies (three bladder cancer and one kidney cancer).
Urine dipstick testing during lung cancer screenings in patients with significant smoking histories may facilitate early detection of urological malignancies, potentially improving patient outcomes. Further research is required to validate these findings, determine cost-effectiveness, and develop standardized screening strategies.
膀胱癌,特别是尿路上皮癌(UC),在美国是一个重大的健康问题,并且受到烟草使用的显著影响。尽管其发病率较高,但由于诊断局限性以及对长期生存的益处不确定,不建议进行常规UC筛查。
本研究考察了在因大量吸烟史而已经处于UC高风险的受试者中,使用尿试纸条筛查UC的有效性,这些受试者正在接受低剂量计算机断层扫描(LDCT)进行肺癌筛查。
在一个单一的学术中心进行了一项前瞻性研究,以筛查接受年度LDCT肺癌筛查的患者是否患有UC。对没有肉眼血尿病史或先前未被诊断为患有UC的患者进行尿试纸条检测。使用统计分析来评估吸烟史、尿液分析结果与泌尿系统恶性肿瘤患病率之间的关系。
我们纳入了201名患者,平均年龄为64.4岁,性别分布均衡。尿试纸条检测在15%的患者中检测到红细胞(RBC),其中2.1%在正式尿液分析中显示为镜下血尿(>2个RBC/高倍视野)。九名(4.5%)参与者被建议进行全面的血尿评估。此外,四名(2%)参与者有泌尿系统恶性肿瘤病史或新被诊断为患有泌尿系统恶性肿瘤(三例膀胱癌和一例肾癌)。
在有显著吸烟史的患者进行肺癌筛查期间进行尿试纸条检测,可能有助于早期发现泌尿系统恶性肿瘤,潜在地改善患者预后。需要进一步的研究来验证这些发现、确定成本效益并制定标准化的筛查策略。